Analyze Diet

Topic:Vaccine

Vaccination in horses involves the administration of biological preparations designed to stimulate the equine immune system to recognize and combat specific pathogens. Vaccines are formulated to prevent or reduce the severity of infectious diseases that can affect equine health and performance. Common vaccines for horses include those for equine influenza, tetanus, equine herpesvirus, and West Nile virus. The administration schedule and type of vaccine can vary based on factors such as geographic location, age, and use of the horse. This page compiles peer-reviewed research studies and scholarly articles that explore the development, efficacy, and safety of vaccines in horses, as well as their impact on equine health management.
Outcome of tactile conditioning of neonates, or “imprint training” on selected handling measures in foals.
Veterinary journal (London, England : 1997)    October 27, 2004   Volume 168, Issue 3 252-258 doi: 10.1016/j.tvjl.2003.12.008
Spier SJ, Berger Pusterla J, Villarroel A, Pusterla N.Behavioural reactions to selected handling procedures were compared between conditioned, or imprint-trained, and untrained foals raised on the same farm. Nineteen randomly chosen healthy foals were imprint trained at birth and 24 h later (Group A). Twenty-one similar foals that were not imprint-trained served as age-matched controls (Group B). Training began within 10 min of birth and consisted of touch desensitization by gentle rubbing. Each tactile stimulus was repeated 30-50 times over 45-60 min, until the foal no longer resisted the procedure and appeared relaxed. The procedure was then re...
Evidence supporting the inclusion of strains from each of the two co-circulating lineages of H3N8 equine influenza virus in vaccines.
Vaccine    September 15, 2004   Volume 22, Issue 29-30 4101-4109 doi: 10.1016/j.vaccine.2004.02.048
Daly JM, Yates PJ, Newton JR, Park A, Henley W, Wood JL, Davis-Poynter N, Mumford JA.Two lineages of antigenically distinct equine influenza A H3N8 subtype viruses, American and European, co-circulate. Experiments were conducted in ponies to investigate the protection induced by vaccines containing virus from one lineage against challenge infection with homologous or heterologous virus. Regression analysis showed that vaccinated ponies with average pre-challenge single radial haemolysis (SRH) antibody levels (i.e. 45-190mm2) had a higher probability of becoming infected if they were vaccinated with virus heterologous to the challenge strain than if they were vaccinated with ho...
Evidence that use of an inactivated equine herpesvirus vaccine induces serum cytotoxicity affecting the equine arteritis virus neutralisation test.
Vaccine    September 15, 2004   Volume 22, Issue 29-30 4117-4123 doi: 10.1016/j.vaccine.2004.02.052
Newton JR, Geraghty RJ, Castillo-Olivares J, Cardwell JM, Mumford JA.Several laboratories worldwide have recently experienced problems related to serum cytotoxicity with the equine arteritis virus (EAV) neutralisation test (VN) when using Office International des Epizooties (OIE) reference laboratory prescribed rabbit kidney (RK-13) indicator cells. Cytotoxicity can be mistaken for viral cytopathic effect and has led to increasing difficulties in test interpretation, consequently causing disruption to both equine breeding and disease surveillance. Results from experimental and field-derived data suggest that this serum cytotoxicity is associated with use of a t...
Humoral response to West Nile virus vaccination in alpacas and llamas.
Journal of the American Veterinary Medical Association    August 27, 2004   Volume 225, Issue 3 414-416 doi: 10.2460/javma.2004.225.414
Kutzler MA, Baker RJ, Mattson DE.To determine humoral responses to an equine West Nile virus (WNV) vaccine in healthy alpacas and llamas and compare responses in alpacas and llamas with responses in horses. Methods: Clinical trial. Methods: 28 alpacas, 56 llamas, and 16 horses. Methods: Horses received 2 vaccinations at 4-week intervals, and alpacas and llamas received 3 vaccinations at 3-week intervals. Fifty-five llamas received a fourth vaccination 3 weeks after the third. Blood samples were collected immediately prior to each vaccination, 3 weeks after the last vaccination for alpacas and llamas, and 4 weeks after the las...
The effects of strain heterology on the epidemiology of equine influenza in a vaccinated population.
Proceedings. Biological sciences    August 13, 2004   Volume 271, Issue 1548 1547-1555 doi: 10.1098/rspb.2004.2766
Park AW, Wood JL, Daly JM, Newton JR, Glass K, Henley W, Mumford JA, Grenfell BT.We assess the effects of strain heterology (strains that are immunologically similar but not identical) on equine influenza in a vaccinated population. Using data relating to individual animals, for both homologous and heterologous vaccinees, we estimate distributions for the latent and infectious periods, quantify the risk of becoming infected in terms of the quantity of cross-reactive antibodies to a key surface protein of the virus (haemagglutinin) and estimate the probability of excreting virus (i.e. becoming infectious) given that infection has occurred. The data suggest that the infectio...
West Nile virus vaccines.
Expert opinion on biological therapy    July 23, 2004   Volume 4, Issue 8 1295-1305 doi: 10.1517/14712598.4.8.1295
Hall RA, Khromykh AA.West Nile virus (WNV) is a mosquito-borne flavivirus that is emerging as a global pathogen. In the last decade, virulent strains of the virus have been associated with significant outbreaks of human and animal disease in Europe, the Middle East and North America. Efforts to develop human and veterinary vaccines have taken both traditional and novel approaches. A formalin-inactivated whole virus vaccine has been approved for use in horses. DNA vaccines coding for the structural WNV proteins have also been assessed for veterinary use and have been found to be protective in mice, horses and birds...
Efficacy of a live equine herpesvirus-1 (EHV-1) strain C147 vaccine in foals with maternally-derived antibody: protection against EHV-1 infection.
Equine veterinary journal    July 16, 2004   Volume 36, Issue 5 447-451 doi: 10.2746/0425164044868332
Patel JR, Didlick S, Bateman H.Currently, there is no recommended immunoprophylaxis against febrile respiratory diseases due to equine herpesvirus-1 (EHV-1) and -4 (EHV-4) in horses below age 5-6 months. This is because of interference by maternally-derived antibody (MDA) of vaccines. Objective: Unweaned equine foals are an important reservoir of EHV-1 transmission; therefore, we experimentally assessed the efficacy of a live EHV-1 vaccine in foals age 1.4-3.5 months with MDA. Methods: Following vaccination and challenge, parameters assessed were virus shedding in nasal mucus, leucocyte-associated viraemia, circulating viru...
Current perspectives on control of equine influenza.
Veterinary research    July 9, 2004   Volume 35, Issue 4 411-423 doi: 10.1051/vetres:2004023
Daly JM, Newton JR, Mumford JA.Influenza A viruses of the H3N8 subtype are a major cause of respiratory disease in horses. Subclinical infection with virus shedding can occur in vaccinated horses, particularly where there is a mismatch between the vaccine strains and the virus strains circulating in the field. Such infections contribute to the spread of the disease. Rapid diagnostic techniques are available for detection of virus antigen and can be used as an aid in control programmes. Improvements have been made to methods of standardising inactivated virus vaccines, and a direct relationship between vaccine potency measur...
DNA vaccines–back in the saddle again?
Nature biotechnology    July 2, 2004   Volume 22, Issue 7 799-801 doi: 10.1038/nbt0704-799
Powell K.A promising new horse vaccine may reignite enthusiasm for DNA vaccine technology in designing prophylactics against infectious disease. Kendall Powell reports.
Detection of EHV-1 and EHV-4 DNA in unweaned Thoroughbred foals from vaccinated mares on a large stud farm.
Equine veterinary journal    May 28, 2004   Volume 36, Issue 4 341-345 doi: 10.2746/0425164044890634
Foote CE, Love DN, Gilkerson JR, Whalley JM.A silent cycle of equine herpesvirus 1 infection has been described following epidemiological studies in unvaccinated mares and foals. In 1997, an inactivated whole virus EHV-1 and EHV-4 vaccine was released commercially in Australia and used on many stud farms. However, it was not known what effect vaccination might have on the cycle of infection of EHV-1. Objective: To investigate whether EHV-1 and EHV-4 could be detected in young foals from vaccinated mares. Methods: Nasal and blood samples were tested by PCR and ELISA after collection from 237 unvaccinated, unweaned foals and vaccinated an...
Evaluation of immune responses in horses immunized using a killed Sarcocystis neurona vaccine.
Veterinary therapeutics : research in applied veterinary medicine    May 20, 2004   Volume 5, Issue 1 34-42 
Marsh AE, Lakritz J, Johnson PJ, Miller MA, Chiang YW, Chu HJ.Clinically normal horses developed cellular immunity to Sarcocystis neurona following IM vaccination with a commercial killed S. neurona vaccine, as indicated by the development of measurable anti-S. neurona IgG antibodies and additional intradermal skin testing. Large-scale independent assessments of the vaccine's performance and safety are in progress under field conditions. The next step in the evaluation of this vaccine would be to attempt experimental challenge after a reproducible reliable equine model of S. neurona encephalitis has been established that allows for reisolation of the pat...
Serologic responses to eastern and western equine encephalomyelitis vaccination in previously vaccinated horses.
Veterinary therapeutics : research in applied veterinary medicine    May 12, 2004   Volume 4, Issue 3 242-248 
Waldridge BM, Wenzel JG, Ellis AC, Rowe-Morton SE, Bridges ER, D'Andrea G, Wint R.A prospective study was performed to determine the serologic response of previously vaccinated horses to revaccination against eastern and western equine encephalomyelitis (EEE and WEE). Horses responded variably to each antigen, and some horses had low or undetectable antibodies 6 months after vaccination. Some horses did not develop increasing titers to EEE or WEE despite recent vaccination. Geometric mean titers peaked 2 weeks after revaccination and were significantly increased from before revaccination. Except for one horse, EEE:WEE titer ratios ranged from 0.25 to 2.0. Regular vaccinatio...
Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge.
Archives of virology. Supplementum    May 4, 2004   Issue 18 221-230 doi: 10.1007/978-3-7091-0572-6_20
Minke JM, Siger L, Karaca K, Austgen L, Gordy P, Bowen R, Renshaw RW, Loosmore S, Audonnet JC, Nordgren B.An ALVAC (canarypoxvirus)-based recombinant (vCP2017) expressing the prM and E genes derived from a 1999 New York isolate of West Nile virus (WNV) was constructed and assessed for its protective efficacy in horses in two different experiments. In the first trial, a dose titration study was conducted to evaluate both serum neutralising antibody responses to WNV and duration of immunity. In the second trial the onset of protection was determined. Twenty-eight adult horses received two doses of vCP2017 administered intramuscularly at 5-week intervals and sixteen horses comprised age-matched non-v...
Seroprevalence of equine herpesvirus 1 in mares and foals on a large Hunter Valley stud farm in years pre- and postvaccination.
Australian veterinary journal    April 16, 2004   Volume 81, Issue 5 283-288 doi: 10.1111/j.1751-0813.2003.tb12576.x
Foote CE, Gilkerson JR, Whalley JM, Love DN.To examine the prevalence of equine herpesvirus 1 antibody in mares and foals on a large Hunter Valley Thoroughbred stud farm in New South Wales before and after the introduction of an inactivated whole virus vaccine. Methods: Cross-sectional serological surveys performed in February 1995 and 2000 to determine the prevalence of EHV-1 antibody-positive mares and foals. A further cross-sectional survey was carried out in 2001 to complement the 2000 data. Methods: Two hundred and twenty-nine mares and their foals were sampled in 1995 and 236 mares and their foals were sampled in 2000. The study p...
Prevalence of antibody to Japanese encephalitis virus nonstructural 1 protein among racehorses in Japan: indication of natural infection and need for continuous vaccination.
Vaccine    March 9, 2004   Volume 22, Issue 9-10 1097-1103 doi: 10.1016/j.vaccine.2003.10.001
Konishi E, Shoda M, Kondo T.Japanese encephalitis virus (JEV) causes fatal diseases in equines as well as humans. In Japan, racehorses are vaccinated with inactivated JE vaccine every year and no equine JE cases have been reported since 1986. However, the current reduction in JEV activity in nature has raised an argument against the requirement of continuous vaccination. Here, we studied natural infection rates in racehorses to address the issue. To identify naturally-infected individuals from vaccinated populations, we used an immunostaining method for detecting antibodies to JEV nonstructural 1 (NS1) protein. A total o...
Updating equine influenza strains in a combined equine influenza and herpesvirus vaccine.
Veterinary journal (London, England : 1997)    February 21, 2004   Volume 167, Issue 2 118-120 doi: 10.1016/S1090-0233(03)00034-0
Cullinane AA.No abstract available
Efficacy and duration of immunity of a combined equine influenza and equine herpesvirus vaccine against challenge with an American-like equine influenza virus (A/equi-2/Kentucky/95).
Veterinary journal (London, England : 1997)    February 21, 2004   Volume 167, Issue 2 150-157 doi: 10.1016/S1090-0233(03)00028-5
Heldens JG, Pouwels HG, van Loon AA.It has been recommended that modern equine influenza vaccines should contain an A/equi-1 strain and A/equi-2 strains of the American and European-like subtype. We describe here the efficacy of a modern updated inactivated equine influenza-herpesvirus combination vaccine against challenge with a recent American-like isolate of equine influenza (A/equine-2/Kentucky/95 (H3N8). The vaccine contains inactivated Influenza strains A-equine-1/Prague'56, A-equine-2/Newmarket-1/'93 (American lineage) and A-equine-2/ Newmarket-2/93 (Eurasian lineage) and inactivated EHV-1 strain RacH and EHV-4 strain V22...
Sarcocystis neurona-specific immunoglobulin G in the serum and cerebrospinal fluid of horses administered S neurona vaccine.
Journal of veterinary internal medicine    February 10, 2004   Volume 18, Issue 1 98-103 doi: 10.1892/0891-6640(2004)18<98:snigit>2.0.co;2
Witonsky S, Morrow JK, Leger C, Dascanio J, Buechner-Maxwell V, Palmer W, Kline K, Cook A.A vaccine against Sarcocystis neurona, which induces equine protozoal myeloencephalitis (EPM), has received conditional licensure in the United States. A major concern is whether the immunoglobulin G (IgG) response elicited by the vaccine will compromise the use of Western blotting (WB) as a diagnostic tool in vaccinated horses with neurologic disease. Our goals were to determine if vaccination (1) causes seroconversion: (2) causes at least a transient increase in S neurona-specific IgG in the cerebrospinal fluid (CSF); and (3) induces an IgG response that can be differentiated from that induc...
Equine vaccine for West Nile virus.
Developments in biologicals    December 18, 2003   Volume 114 221-227 
Ng T, Hathaway D, Jennings N, Champ D, Chiang YW, Chu HJ.To meet the urgent need of controlling West Nile virus (WNV) infection in the equine population, we have developed a killed WNV vaccine. A dose titration study in horses was first conducted to evaluate serum neutralization antibody responses against WNV in these animals. Horses were vaccinated intramuscularly twice with the test vaccine at low, medium and high dose, three weeks apart. Serum samples were collected periodically and were measured for serum neutralizing antibody using a plaque reduction neutralization test. Significant increases in serum neutralizing antibody were detected in all ...
Lyme borreliosis.
Journal of the American Veterinary Medical Association    November 19, 2003   Volume 223, Issue 9 1261-1270 doi: 10.2460/javma.2003.223.1261
Fritz CL, Kjemtrup AM.Despite more than 25 years' experience with Lyme borreliosis, much remains to be learned about this complex zoonosis. Practicing veterinarians, particularly those in the northeastern and upper midwestern states, where Lyme borreliosis is highly endemic, should be familiar with the ecologic features and typical clinical signs of Lyme borreliosis. Interpretation of signs and serologic test results should be made with consideration of the regional prevalence of Lyme borreliosis and the animal's opportunity for exposure to infected Ixodes spp. The availability of recently marketed topical acaracid...
APHIS: West Nile virus vaccine safe for use.
Journal of the American Veterinary Medical Association    August 22, 2003   Volume 223, Issue 4 416-418 
Kahler SC.No abstract available
Analysis of anamnestic immune responses in adult horses and priming in neonates induced by a DNA vaccine expressing the vapA gene of Rhodococcus equi.
Vaccine    August 19, 2003   Volume 21, Issue 25-26 3815-3825 doi: 10.1016/s0264-410x(03)00329-3
Lopez AM, Hines MT, Palmer GH, Knowles DP, Alperin DC, Hines SA.Rhodococcus equi remains one of the most important pathogens of early life in horses, yet conventional vaccines to prevent rhodococcal pneumonia have not been successful. DNA vaccination offers an alternative to conventional vaccines with specific advantages for immunization of neonates. We developed a DNA vaccine expressing the vapA gene (pVR1055vapA) that induced an anamnestic response characterized by virulence associated protein A (VapA)-specific IgG antibodies in sera and bronchoalveolar lavage fluid (BALF) as well as VapA-specific proliferation of pulmonary lymphocytes when tested in adu...
Comparison of hamster and pony challenge models for evaluation of effect of antigenic drift on cross protection afforded by equine influenza vaccines.
Equine veterinary journal    July 24, 2003   Volume 35, Issue 5 458-462 doi: 10.2746/042516403775600433
Daly JM, Yates RJ, Browse G, Swann Z, Newton JR, Jessett D, Davis-Poynter N, Mumford JA.Vaccination and challenge studies in ponies are the most relevant experimental system for predicting whether strains included in equine influenza vaccines are relevant, but they are difficult to perform. Objective: In order to investigate the feasibility of using a small animal model, results of a cross-protection study in hamsters were compared with those from a previous pony challenge experiment. Methods: Animals were immunised with inactivated vaccines containing one of 4 strains of equine influenza A H3N8 subtype virus isolated over a 26 year period (1963 to 1989), then challenged with a 1...
Regional antibody and cellular immune responses to equine influenza virus infection, and particle mediated DNA vaccination.
Veterinary immunology and immunopathology    July 5, 2003   Volume 94, Issue 1-2 47-62 doi: 10.1016/s0165-2427(03)00060-6
Soboll G, Horohov DW, Aldridge BM, Olsen CW, McGregor MW, Drape RJ, Macklin MD, Swain WF, Lunn DP.We have previously demonstrated that hemagglutinin (HA) gene vaccination and influenza virus infection generate protective antibody responses in equids. However, these antibody responses differ substantially in that particle mediated DNA vaccination does not induce an immunoglobulin A (IgA) response. A study was performed to investigate the regional immunoregulatory mechanisms associated with these different immune responses. Ponies were either vaccinated with equine HA DNA vaccines at skin and mucosal sites, infected with influenza virus or left untreated and influenza-specific antibody respo...
[A new product in the vaccination gap: the vector vaccine. Merial introduced an innovative influenza-tetanus vaccine for horses].
Tijdschrift voor diergeneeskunde    May 29, 2003   Volume 128, Issue 9 295-296 
Hulsen J.No abstract available
West Nile virus encephalomyelitis in horses: 46 cases (2001).
Journal of the American Veterinary Medical Association    May 3, 2003   Volume 222, Issue 9 1241-1247 doi: 10.2460/javma.2003.222.1241
Porter MB, Long MT, Getman LM, Giguère S, MacKay RJ, Lester GD, Alleman AR, Wamsley HL, Franklin RP, Jacks S, Buergelt CD, Detrisac CJ.To determine signalment, clinical findings, results of diagnostic testing, outcome, and postmortem findings in horses with West Nile virus (WNV) encephalomyelitis. Methods: Retrospective study. Methods: 46 horses with WNV encephalomyelitis. Methods: Clinical data were extracted from medical records of affected horses. Results: On the basis of clinical signs and results of serologic testing, WNV encephalomyelitis was diagnosed in 46 of 56 horses with CNS signs. Significantly more males than females were affected. Increased rectal temperature, weakness or ataxia, and muscle fasciculations were t...
Limited potential for mosquito transmission of genetically engineered, live-attenuated western equine encephalitis virus vaccine candidates.
The American journal of tropical medicine and hygiene    March 19, 2003   Volume 68, Issue 2 218-221 
Turell MJ, O'Guinn ML, Parker MD.Specific mutations associated with attenuation of Venezuelan equine encephalitis (VEE) virus in rodent models were identified during efforts to develop an improved VEE vaccine. Analogous mutations were produced in full-length cDNA clones of the Cba 87 strain of western equine encephalitis (WEE) virus by site-directed mutagenesis in an attempt to develop an improved WEE vaccine. Isogenic viral strains with these mutations were recovered after transfection of baby hamster kidney cells with infectious RNA. We evaluated two of these strains (WE2102 and WE2130) for their ability to replicate in and...
Venezuelan equine encephalitis virus-vectored vaccines protect mice against anthrax spore challenge.
Infection and immunity    February 22, 2003   Volume 71, Issue 3 1491-1496 doi: 10.1128/IAI.71.3.1491-1496.2003
Lee JS, Hadjipanayis AG, Welkos SL.Anthrax, a disease usually associated with herbivores, is caused by the bacterium Bacillus anthracis. The current vaccine licensed for human use requires a six-dose primary series and yearly boosters and causes reactogenicity in up to 30% of vaccine recipients. A minimally reactogenic vaccine requiring fewer inoculations is warranted. Venezuelan equine encephalitis (VEE) virus has been configured for use as a vaccine vector for a wide variety of immunogens. The VEE vaccine vector is composed of a self-replicating RNA (replicon) containing all of the VEE virus nonstructural genes and a multiple...
Occurrence of infectious upper respiratory tract disease and response to vaccination in horses on six sentinel premises in northern Colorado.
Equine veterinary journal    January 30, 2003   Volume 35, Issue 1 72-77 doi: 10.2746/042516403775467379
Mumford EL, Traub-Dargatz JL, Carman J, Callan RJ, Collins JK, Goltz KL, Romm SR, Tarr SF, Salman MD.Horses vaccinated against common agents of infectious upper respiratory disease (IURD) may not have detectable serum antibody and may not be protected from clinical disease. Objective: The objectives of this study were to 1) investigate the serological response of horses to vaccination against influenza virus (H3N8 and H7N7) and equine herpesviruses (EHV) in a field setting and 2) evaluate associations among vaccination status, serum antibody concentrations, and occurrences of IURD in monitored horses. Methods: In this study, horses on 6 Colorado premises were vaccinated parenterally against i...
Equid herpesvirus (EHV-1) live vaccine strain C147: efficacy against respiratory diseases following EHV types 1 and 4 challenges.
Veterinary microbiology    December 19, 2002   Volume 92, Issue 1-2 1-17 doi: 10.1016/s0378-1135(02)00358-9
Patel JR, Földi J, Bateman H, Williams J, Didlick S, Stark R.The temperature sensitive and host range mutant clone 147 of equine herpesvirus 1 (EHV-1) was assessed for its ability to protect conventional, susceptible adult horses against respiratory infection by EHV-1 and equine herpesvirus 4 (EHV-4). Intranasal (IN) vaccination with 5.2 log(10) TCID(50) did not cause adverse clinical reactions although a limited virus shedding and viraemia (leukocytes) was observed in 11 of 15 and 10 of 15 vaccinated horses respectively. All 15 vaccinated horses showed a significant seroresponse to both EHV-1 and EHV-4 for virus neutralising (VN) antibody. None of 14 c...
1 16 17 18 19 20 29